FDA approves nasal spray to treat migraines, promising ‘efficacy on demand’

Impel NeuroPharma, a Seattle-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration last week for its novel nasal spray that treats migraine headaches. The therapeutic, called Trudhesa, involves the use of Impel’s patented device called the POD, which sprays dihydroergotamine mesylate (DHE) into patients’ noses more precisely so it reaches the upper […]

Continue Reading